Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.

This study is testing a CAR-T cell therapy called inaticabtagene autoleucel combined with a stem cell transplant for adolescents and adults with B-cell acute lymphoblastic leukemia (a blood cancer) who are in remission but still have detectable cancer cells (called MRD-positive, or minimal residual disease). The goal is to eliminate those remaining cancer cells and prevent relapse. **You may be eligible if...** - You are newly diagnosed with B-cell ALL and achieved remission after initial chemotherapy - You still have detectable cancer cells (MRD positive) in your bone marrow after consolidation therapy - You are physically well enough for a stem cell transplant - Your organs are functioning adequately **You may NOT be eligible if...** - You have Burkitt lymphoma/leukemia or certain other subtypes of leukemia - You have significant organ dysfunction - You are not a candidate for autologous stem cell transplantation Talk to your doctor to see if this trial is right for you.